Abstract
Cochleates containing amphotericin B (CAMB) were administered orally at doses ranging from 0 to 40 mg/kg of body weight/day for 14 days in a murine model of systemic aspergillosis. The administration of oral doses of CAMB (20 and 40 mg/kg/day) resulted in a survival rate of 70% and a reduction in colony counts of more than 2 logs in lungs, livers, and kidneys. Orally administered CAMB shows promise for the treatment of aspergillosis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Amphotericin B / administration & dosage*
-
Amphotericin B / pharmacokinetics
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / administration & dosage*
-
Antifungal Agents / pharmacokinetics
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy*
-
Aspergillosis / microbiology
-
Deoxycholic Acid / administration & dosage*
-
Deoxycholic Acid / analogs & derivatives*
-
Deoxycholic Acid / pharmacokinetics
-
Deoxycholic Acid / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Female
-
Kidney / metabolism
-
Kidney / microbiology
-
Liver / metabolism
-
Liver / microbiology
-
Lung / metabolism
-
Lung / microbiology
-
Mice
-
Mice, Inbred BALB C
-
Pharmaceutical Vehicles
-
Survival Analysis
-
Tissue Distribution
Substances
-
Antifungal Agents
-
Drug Combinations
-
Pharmaceutical Vehicles
-
Deoxycholic Acid
-
Amphotericin B
-
amphotericin B, deoxycholate drug combination